证券代码：600713 证券简称：南京医药 编号：ls2025-076 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于可转换公司债券 2025 年度跟踪评级结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司前次主体信用等级为"AA+"，评级展望为"稳定"；"南药转债"前 次信用等级为"AA+"；评级机构为中诚信，评级时间为 2024 年 12 月 4 日。 中诚信在对本公司经营状况、行业情况进行综合分析与评估的基础上，于 评委函字2025跟踪 0283 号），本次公司主体信用等级为"AA+"，评级展望 维持"稳定"；"南药转债"信用等级为"AA+"。评级结果较前次评级没有变 化。 公司于同日披露上述《南京医药股份有限公司 2025 年度跟踪评级报告》 （信 评委函字2025跟踪 0283 号）全文，详见上海证券交易所网站（http://www.sse. com.cn） 特此公告 南京医药股份有限公司董事会 ? 前次跟踪评级结果：主体信用等级为"AA+"，评级展望为"稳定"， ...

Key Points - The company announced the interest payment schedule for its convertible bonds, "长汽转债," with the interest payment date set for June 10, 2025 [1][4] - The total face value of the convertible bonds issued is 3.5 billion RMB, with an annual interest rate of 0.80% for the current interest period [1][3] - The interest payment will be made to all registered holders of the convertible bonds as of the record date, June 9, 2025 [4][5] - The interest income for individual investors will be subject to a 20% tax, resulting in a net payment of 0.64 RMB per bond after tax [5][6] - Non-resident enterprises holding the bonds will be exempt from corporate income tax on the interest income until December 31, 2025 [5]

Core Viewpoint - The company, Lingnan Ecological Culture and Tourism Co., Ltd., is facing significant financial difficulties, including the inability to repay its convertible bonds on time, which may lead to further legal and operational challenges [2][4][6]. Financial Performance - In 2024, the company's operating revenue was 861.84 million yuan, a decline of 59.55% compared to 2023 [3]. - The net profit attributable to shareholders for 2024 was -984.33 million yuan, indicating a reduction in the scale of losses compared to 2023 [3]. - For the first quarter of 2025, the net profit attributable to shareholders was -66.40 million yuan, a decrease of 26.36% in losses compared to the same period in 2024 [3]. Bond Default Risk - The company announced that it could not make timely principal and interest payments on the "Lingnan Convertible Bonds," leading to a downgrade of its credit rating to C [2][4]. - The default on the bonds may undermine creditor confidence, further straining the company's financing capabilities and exacerbating its liquidity issues [2][4]. Operational Challenges - The company has faced significant impacts on its ecological environment construction, water management, and cultural tourism businesses, resulting in delayed project bidding and construction [2][4]. - The high asset-liability ratio and declining profitability have led to ongoing liquidity pressures [2][4]. Legal and Regulatory Risks - As of December 31, 2024, the company had 251 pending lawsuits with a total amount in dispute of 2.95 billion yuan [6][7]. - The company is at risk of being delisted if its stock price remains below 1 yuan for 20 consecutive trading days [6]. Pledge and Collateral Risks - The company has pledged its receivables and equity from project companies as collateral for the convertible bonds, but the realizable value of these assets is uncertain due to long collection periods and lack of market reference [5][6]. - There are risks associated with the potential bankruptcy of the company within a year of the collateral establishment, which could lead to the revocation of the pledge [5][6]. Management and Oversight - GF Securities has been appointed as the trustee for the convertible bonds and is monitoring the situation closely to protect the interests of bondholders [8]. - The company has proposed a delay in certain fundraising projects, extending the completion date to May 2026 [8].

股票代码：002822 股票简称：ST 中装 债券代码：127033 债券简称：中装转 2 深圳市中装建设集团股份有限公司 公开发行可转换公司债券 第二次临时受托管理事务报告 （2025 年度） 债券受托管理人 二〇二五年五月 重要声明 本报告依据《公司债券发行与交易管理办法》 （以下简称"《管理办法》"）、 《深圳 市中装建设集团股份有限公司与东兴证券股份有限公司关于公开发行可转换公司债 券之受托管理协议》 （以下简称"《受托管理协议》"）、 《深圳市中装建设集团股份有限 公司公开发行可转换公司债券募集说明书》 （以下简称"《募集说明书》"）等相关公开 信息披露文件，由本次可转债受托管理人东兴证券股份有限公司（以下简称"东兴证 券"）编制。东兴证券对本报告中所包含的从上述文件中引述内容和信息未进行独立 验证，也不就该等引述内容和信息的真实性、准确性和完整性做出任何保证或承担任 何责任。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关事宜 做出独立判断，而不应将本报告中的任何内容据以作为东兴证券所作的承诺或声明。 在任何情况下，投资者依据本报告所进行的任何作为或不作为，东兴证券不承担任何 ...

Group 1 - The core announcement is regarding the results of the "Lixun Convertible Bonds" repurchase, which was disclosed on multiple dates in May 2025 [1][2] - The repurchase price for the bonds is set at RMB 100.981 per bond, including interest and tax [1] - The effective number of repurchase applications received was 11 bonds, with a total repurchase amount not specified in the document [1][2] Group 2 - The repurchase will not have a substantial impact on the company's financial status, operating results, cash flow, or capital structure [2] - The company will continue to trade the unrepurchased "Lixun Convertible Bonds" on the Shenzhen Stock Exchange [2]

一、本次向不特定对象发行可转换公司债券摊薄即期回报对公司主要财务指标 的影响 在公司股本有所增加的情况下，可能导致公司发行当年利润增长幅度低于股 本的扩张幅度，公司每股收益在发行后的一定期间内将会被摊薄，公司即期回报 存在被摊薄的风险。 在不考虑本次募集资金使用效益的前提下，根据下述假设条件，本次发行主 要财务数据和财务指标的影响的模拟测算如下： （一）主要假设和前提条件 证券代码：300751 证券简称：迈为股份 公告编号：2025-027 苏州迈为科技股份有限公司 关于向不特定对象发行可转换公司债券摊薄即期回报与填 补回报措施及相关主体承诺的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 苏州迈为科技股份有限公司（以下简称"公司"）于 2025 年 5 月 30 日召开 了第三届董事会第十四次会议，审议通过了《关于公司向不特定对象发行可转换 公司债券预案的议案》。 为进一步落实《国务院关于进一步促进资本市场健康发展的若干意见》（国 发201417 号）、《国务院办公厅关于进一步加强资本市场中小投资者合法权益 保护工作的意见》（国办发2013110 号 ...

证券代码：300751 证券简称：迈为股份 公告编号：2025-030 苏州迈为科技股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 苏州迈为科技股份有限公司第三届监事会第十四次会议通知于 2025 年 5 月 在苏州市吴江区大兢路 8 号办公楼 1 楼会议室以现场会议结合通讯表决的方式召 开。本次会议应出席会议监事 3 人，实际参加监事 3 人，会议由监事会主席施政 辉主持，公司董事会秘书列席了会议。本次会议的召集、召开和表决程序符合有 关法律、法规和《公司章程》的规定，会议形成的决议合法有效。 二、监事会会议审议情况 本次会议以记名方式投票表决，审议通过以下事项： 案》 根据《公司法》 《证券法》以及《上市公司证券发行注册管理办法》等法律、 法规及规范性文件的相关规定，公司监事会经过对公司实际情况逐项自查核对， 认为公司各项条件符合现行法律、法规及规范性文件中关于创业板上市公司向不 特定对象发行可转换公司债券的规定，具备向不特定对象发行可转换公司债券的 条件。 本议案须提请股东大会审议通过。 表决结果：同意 3 票；反对 ...

Group 1 - The company Guangzhou Jiacheng International Logistics Co., Ltd. issued convertible bonds totaling RMB 800 million, with a maturity of 6 years and a net fundraising amount of RMB 793.8213 million after deducting issuance costs [1][17]. - The bonds have a face value of RMB 100 each, with an annual interest rate that increases from 0.30% in the first year to 3.00% in the sixth year [2][3]. - The initial conversion price for the bonds is set at RMB 22.98 per share, with provisions for adjustments based on various corporate actions [4][5]. Group 2 - The company operates in the logistics industry, providing customized logistics solutions and comprehensive supply chain services, particularly for manufacturing and e-commerce clients [17]. - The company has a registered capital of RMB 345,211,243 and was established on October 24, 2000, with its headquarters located in Guangzhou [17]. - The company’s main business includes international freight forwarding, warehousing, and supply chain management services, catering to both domestic and international markets [17]. Group 3 - The bonds are listed on the Shanghai Stock Exchange under the code "113656" and are subject to specific terms regarding interest payments, conversion rights, and redemption options [1][10]. - The company has established a fundraising management system to ensure that the raised funds are used according to the planned projects, including the "Cross-border E-commerce Smart Logistics Center" and "Free Trade Port Cloud Intelligence International Distribution Center" [17]. - The company has received a credit rating of AA- for both its corporate and bond ratings, indicating a stable outlook [17].

一、可转换公司债券募集资金基本情况 （一）可转换公司债券实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意浙江东亚药业股份有限公司向不特 定对象发行可转换公司债券注册的批复》 证券代码：605177 证券简称：东亚药业 公告编号：2025-029 债券代码：111015 债券简称：东亚转债 浙江东亚药业股份有限公司 关于可转换公司债券募集资金投资项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 第四届董事会第八次会议、第四届监事会第七次会议，分别审议通过了《关于可 转换公司债券募集资金投资项目延期的议案》，主要内容如下： 年 7 月 12 日全部到账，并经中汇会计师事务所（特殊普通合伙）审验，于 2023 年 7 月 12 日出具了《债券募集资金到位情况验证报告》 （中汇会验20238458 号）。 （二）可转换公司债券募集资金投资项目的情况 截至 2024 年 12 月 31 日，根据《浙江东亚药业股份有限公司向不特定对象 发行可转换公司债券募集说明书》，公司可转换公司债券募集资金投资项目及募 ...

General Provisions - The rules are established to regulate the organization and behavior of the bondholders' meeting for the issuance of convertible bonds by the company, ensuring the rights and obligations of bondholders are defined and protected [1][2] - The convertible bonds are issued according to the terms outlined in the company's prospectus, and bondholders are defined as investors who acquire these bonds through legal means [2][3] Rights and Obligations of Bondholders - Bondholders have the right to receive interest based on the amount of convertible bonds held, convert their bonds into shares under specified conditions, and participate in bondholders' meetings to exercise voting rights [6] - Bondholders are obligated to comply with the terms of the bond issuance, pay subscription funds, and adhere to valid resolutions made during bondholders' meetings [7] Authority of Bondholders' Meeting - The bondholders' meeting has the authority to make decisions on various matters, including changes to the prospectus, approval of solutions when the company fails to pay interest, and decisions regarding company restructuring or bankruptcy [8][4] - The meeting can also modify the rules governing the bondholders' meetings within legal limits [4] Convening of Bondholders' Meeting - The company's board of directors is responsible for convening the bondholders' meeting within 30 days of receiving a proposal or upon the occurrence of specific events [5][6] - Bondholders holding more than 10% of the total outstanding bonds can propose a meeting [6] Meeting Procedures - The meeting can be held in person or via communication methods, and the chairman of the meeting is responsible for overseeing the proceedings [25][26] - Bondholders or their proxies must present identification and proof of bond ownership to attend the meeting [22][10] Voting and Resolutions - Each bond has one vote, and resolutions require approval from more than half of the voting bondholders present at the meeting [30][38] - The results of the voting must be announced and recorded, and the resolutions are binding on all bondholders [36][39] Record Keeping and Legal Compliance - The company must maintain records of the meeting, including attendance, voting results, and any legal opinions provided [41][42] - Any disputes regarding the validity of the meeting or resolutions must be resolved through litigation in the jurisdiction where the company is located [49]